Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to the 2009 Deferred Annual Bonus Plan.
Share acquisition prices noted in the filing:
- Ordinary Shares: 1,268.00 pence per share
- American Depositary Shares (ADSs): $38.74 per ADS
Material Changes
The filing details the acquisition of Ordinary Shares and ADSs by specific Directors and PDMRs through the re-investment of dividends. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of share allocations advised to GSK on October 19, 2015.
Important Facts for Investors to Verify
- Confirmation that the share acquisitions were executed via dividend re-investment under the 2009 Deferred Annual Bonus Plan.
- Verification of the specific number of Ordinary Shares and ADSs acquired by each listed Director and PDMR.
- Confirmation that the transaction price of 1,268.00 pence (Ordinary Shares) and $38.74 (ADSs) reflects the market price at the time of allocation.